Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Stopped Completion after 2 patients then stop due to end of validity of vaccine peptide

Conditions

• Metastatic Melanoma

Interventions

• DRUG: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain